Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
257 results about "Exacerbation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An exacerbation, in medicine, is the worsening of a disease or an increase in its symptoms. Examples includes an acute exacerbation of chronic obstructive pulmonary disease and acute exacerbation of congestive heart failure.
Automatic etiology sequencing system
A system and related method for identifying a trigger event to a patient health-related exacerbation. The system includes at least one sensor configured to collect data related to the patient health-related exacerbation, an analyzer configured to validate the collected data, a patient interface device configured to receive patient inputs to at least one question, and an identifier device configured to receive the patient inputs and collected data and identify the trigger event. The system may also include an expert system configured to receive the patient inputs and the validated collected data and identify a primary patient disease, and a reporting device configured to generate reports related to the identified primary patient disease, patient inputs, and sensed patient conditions.
Owner:CARDIAC PACEMAKERS INC
Method for monitoring autonomic tone
A method for monitoring the progression of the hemodynamic status of a patient by tracking autonomic tone. For example, the method may be applied to patients suffering from heart failure, diabetic neuropathy, cardiac ischemia, sleep apnea and hypertension. An implantable or other ambulatory monitor senses a pulse amplitude signal such as a vascular plethysmography signal. Variations of the signal amplitude on a scale greater than the heartbeat to heartbeat scale are indicative of variations in autonomic tone. A significant reduction in pulse amplitude and pulse amplitude variability are indicative of a heart failure exacerbation or other disease state change. This information may be used to warn the patient or healthcare providers of changes in the patient's condition warranting attention.
Owner:PACESETTER INC
Information management apparatus and method for medical care data, and non-transitory computer readable medium
An information sharing apparatus (management apparatus) for medical care data of a patient body includes a data uploader for classifying the medical care data into confidential data for a primary use in medical care of the patient body, and published data published for a secondary use different from the primary use, to store the confidential data and the published data in a storage medium. A problem event detector monitors the confidential data being added or updated, to check occurrence of a problem event of clinical exacerbation of the patient body. An activation processor checks occurrence of a flag signal for activating relocation of the confidential data to the published data upon the occurrence of the problem event. A relocation unit filters the confidential data at least partially to produce published data upon occurrence of the flag signal after the occurrence of the problem event.
Owner:FUJIFILM CORP
Early warning method and system for chronic disease management
InactiveUS20110184250A1Avoid and mitigate predicted health exacerbationAvoid or mitigate the predicted health exacerbationsMedical simulationHealth-index calculationControl setNetwork on
A computer-implemented method and system are provided for assisting a plurality of patients manage chronic health conditions. The method, for each patient, comprises: (a) receiving information from the patient or a member of a patient care network on an expected patient activity at a given future time period; (b) determining expected transient local ambient conditions in the patient's surroundings during the expected patient activity at the given future time period; (c) predicting health exacerbations for the patient using a stored computer model of the patient based on a desired patient control set-point range, the expected patient activity, and the expected transient local ambient conditions; and (d) proactively sending a message to the patient or a member of the patient care network before the given future time period, the message alerting the patient or a member of the patient care network of the predicted health exacerbations for the patient and identifying one or more corrective actions for the patient to avoid or mitigate the predicted health exacerbations.
Owner:QUVIUM
Hearing aid with Anti-occlusion effect techniques and ultra-low frequency response
InactiveUS20090310805A1Improve sound outputAvoid performance degradationOcclusion effect electronic compensationBone conduction transducer hearing devicesControl signalEngineering
An occluding hearing aid having anti-occlusion effect techniques combined with at least one improvement which, in the preferred embodiment, includes enhancement of acoustic output in the lower-midrange and bass frequency regions, typically between substantially 40 and 500 Hz, which regions are crucial for natural reproduction of multimedia sound and music but are not optimally processed, and generally not provided at all, in prior art hearing aids in order to avoid exacerbation of the occlusion effect. In specific embodiments, the hearing aid of the present invention includes primary or first microphone exposed to external sound plus a secondary or second microphone exposed to sound within an ear canal, in which a signal produced by the secondary microphone is applied as negative feedback to an input of a non-gain controlling signal process and amplifier driving a hearing aid receiver (transducer), whereby, it has been determined by the present inventor, the occlusion effect may be substantially canceled. The hearing aid further comprises at least one of ten combinational improvements each providing substantial performance benefits over known techniques and devices.
Owner:PETROFF MICHAEL
Monitoring hf exacerbation and cardiac resynchronization therapy performance
An exemplary method includes delivering a cardiac resynchronization therapy using an atrio-ventricular delay parameter and an interventricular delay parameter, measuring an atrio-ventricular conduction delay, measuring an interventricular conduction delay, assessing heart failure and / or cardiac resynchronization therapy performance based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay and determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay. Other exemplary technologies are also disclosed.
Owner:PACESETTER INC
Systems and methods for digital predictive disease exacerbation and pre-emptive treatment
InactiveUS20160089089A1Reduce expensesHealth-index calculationEpidemiological alert systemsPre emptive treatmentPatient data
The system described herein collects patient data passively and non-passively via onboard and external sensors, and combines the data with past clinical history to generate digital biomarkers. The collected data can also be further combined with other data generating systems to more accurately predict disease exacerbations. The system monitors the digital biomarkers in real-time, and can detect a change in the disease state prior to clinical decompensation and suggest pre-emptive intervention. The system enables a patient to be treated early in the clinical timeline when the disease exacerbation is at the subclinical level rather than waiting until the disease exacerbation reaches the clinical level. Acting when the exacerbation is at the subclinical level enables preemptive treatment rather than reactive treatment, which is often more cost effective while improving clinical outcomes. The system is able to make the predictions by detecting subclinical changes in digital biomarkers that are generated from respiratory, cardiac, patient reported symptoms, user behaviors, and environmental triggers.
Owner:AEDIO
System and method for determining and verifying disease classification codes
InactiveUS20080086327A1Data processing applicationsMedical automated diagnosisChart datumDisease classification
A system and method for determining an updated disease classification code for a patient within a managed care population consisting of (i) a patient condition processing unit for receiving a plurality of patient-related data, (ii) a diagnosis repository database coupled to the patient condition processing unit for storing a preestablished disease classification code for the patient, and (iii) a disease classification code application tool designed to convert medical chart data of the patient into an observed disease classification code for the patient wherein the observed disease classification code is forwarded to the patient condition processing unit and stored in a diagnosis repository database as the updated disease classification code. The updated disease classification code can then be forwarded to the treating physician, reimbursement agency, or any other agency requiring such data. The patient-related data can consist of analog or electronic information relating to patient descriptions, including diagnosis, symptoms, exacerbations and treatment made by the treating physician, patient enrollment data, patient enrollment data, laboratory data, prescription drug data, insurance claims data, data from a diagnostic medial device (such as a heart monitor), etc.
Owner:QMED
Pre-emptive chronic obstructive pulmonary disease risk notifications based on medicament device monitoring
ActiveUS20170109493A1Prevent COPD exacerbationEasy to manageLocal control/monitoringHealth-index calculationCopd exacerbationControlled drug use
A system and method for providing chronic obstructive pulmonary disease (COPD) exacerbation risk notifications in real time or near-real time is described. Rescue and controller medication events are detected by sensors associated with the patient's medicament device / s, and provide a basis to determine to rescue and controller medication use trends for the patient. This data is analyzed to determine the patient's risk for COPD exacerbation after each event, and is used to send notifications to one or both of the patient and their health care provider.
Owner:RECIPROCAL LABS CORP D B A PROPELLER HEALTH
Instrumented metered-dose inhaler and methods for predicting disease exacerbations
The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Implantable medical device and method for such a device for predicting hf status of a patient
InactiveUS20110166472A1Reduce in quantityLess power consumptionMechanical/radiation/invasive therapiesHealth-index calculationMedicineImplanted device
In an implantable medical device, such as a pacemaker or a cardioverter / defibrillator, and a method for operating such an implantable medical device, heart conditions, such as heart failure, are detected and predicted at an early stage within a patient in whom the medical device is implanted, by monitoring a patient status, for example, HF status, and predicting a worsening of the HF status of the patient and determining a patient status index, wherein a first average and a second average is compared at predetermined sample points of time. A patient status is determined based on this patient status index, wherein a patient status index that has increased substantially monotonously during a first monitoring period is determined to be an indication of an exacerbation of patient status, and in particular, a worsening of heart failure.
Owner:ST JUDE MEDICAL
Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT
Treatment of multiple sclerosis (MS)
The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing / remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing / remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing / remitting disease as seen with multiple sclerosis.
Owner:BIOTEMPT
Vaccine
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Instrumented Metered-Dose Inhaler and Methods for Predicting Disease Exacerbations
ActiveUS20100094099A1Easy to addEnhanced couplingRespiratorsDrug and medicationsInhaled drugRespiratory disease
The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Systems and methods for monitoring and management of chronic disease
PendingUS20200297955A1Improve comfortIncrease costPhysical therapies and activitiesMechanical/radiation/invasive therapiesDiseaseEmergency medicine
Systems and methods assist with managing a chronic disease of a user such as a chronic respiratory or cardiac disease. The system may include a physiological monitor adapted to be carried by the user and operative to sense a physiological parameter of the user. The system may include a management device operatively coupled with the physiological monitor to receive the sensed physiological parameter of the user. The management device, such as with an included processor, may be configured to analyze the physiological and / or environmental parameters to detect a trigger pattern of the parameters, the trigger pattern indicative of a probable event of exacerbation of the chronic respiratory and / or cardiac condition. The management device may then generate automated responses based on the trigger pattern such as by providing instructions for activities and / or treatment for the chronic condition.
Owner:RESMED SENSOR TECH
Methods and apparatus for detecting and treating respiratory insufficiency
The invention discloses apparatus, systems and methods for detecting a severity change in respiratory insufficiency or chronic obstructive pulmonary disease. The supplied pressure may optionally be determined during pressure treatment that satisfies a target ventilation. The supplied pressure or representative data may be compared to one or more thresholds that are selected to represent a change in the condition of the RI or COPD patient such as an exacerbation of a prior condition. Results of the comparisons may trigger one or more warnings or messages to notify a patient or physician of a pending change to the patient's RI or COPD condition so that the patient may more immediately seek medical attention to treat the condition.
Owner:RESMED LTD
Methods of using cgrp for cardiovascular and renal indications
InactiveUS20090023644A1Minimizing and attenuating deleterious effectHormone peptidesDepsipeptidesDiseaseMortality rate
Owner:VASOGENIX PHARMA
Pharmaceutical formulations and methods for treating respiratory tract infections
InactiveUS20120107414A1Good synergyReducing viral replicationAntibacterial agentsBiocideDiseaseProphylactic treatment
The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.
Owner:PULMATRIX
Parenteral preparation containing active entecavir and preparation method thereof
The invention relates to a parenteral preparation containing active entecavir and a preparation method thereof. The invention is characterized in that the parenteral preparation comprises the active entecavir, xylitol, water-soluble filler, pH regulator, water for injection and osmo-regulator, wherein the active entecavir is 0.001 percent to 30 percent by weight, and the balance is pharmaceutic adjuvant or water. The parenteral preparation has the advantages of good stability and high bioavailability, thus solving the defects of the oral administration of entecavir in treating the acute exacerbation of viruses. The parenteral preparation is particularly suitable for treatment on the acute exacerbation of hepatitis of a diabetic.
Owner:TIANJIN PACIFIC PHARMA
N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Antibody pairs and kits for immunochemical determination of mannan-binding lectin
InactiveUS7211396B2Increased to exacerbationIncreased susceptibilityImmunoglobulins against animals/humansEnzymologyDiseaseAutoimmune disease
Various antibodies with different binding characteristics for MBL A or MBL B bound to mannan or MBL A or MBL B bound to an antibody against MBL are provided. Also provided are methods for selecting antibodies against MBL with different binding characteristics and methods and kits for using these antibodies to measure MBL capable of binding to mannan or oligomerized MBL and abnormal, poorly oligomerized MBL in a sample. The methods and kits are useful in diagnosing increased susceptibility to and exacerbation of infections and autoimmune diseases.
Owner:ANTIBODYSHOP
Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection
Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT
Methods and apparatus for monitoring and treating respiratory insufficiency
ActiveUS20130340758A1RespiratorsMechanical/radiation/invasive therapiesObstructive Pulmonary DiseasesCvd risk
An apparatus, such as a pressure support ventilator or respiratory monitor, provides operations for a patient, such a patient with heart failure, Chronic Obstructive Pulmonary Disease or other respiratory insufficiency. In some embodiments, the apparatus may detect a respiratory condition, such as a decompensation event and / or exacerbation event, from respiratory parameters. A clinical alert message may be transmitted or displayed for a physician based on the results of query presented to the patient in response to an analysis of the one or more respiratory parameters. In some embodiments, the apparatus generates a potential relapse indicator that may provide a prediction of a risk of an oncoming clinical event such as for evaluating whether to release the patient from a hospital.
Owner:RESMED SENSOR TECH
Novel Galactoside Inhibitor of Galectins
The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.
Owner:GALECTO BIOTECH
Diagnostic method
InactiveUS20020142294A1Reduce harmInhibit deteriorationMicrobiological testing/measurementPatient managementCurative treatment
The present invention relates to a method for detecting one or more indicator(s) of the probable onset of a chronic obstructive pulmonary disease (COPD) exacerbation; primers for use in the method; a computer model using detection of one or more indicator(s) to the probable onset of a COPD exacerbation for patient management and the prophylactic or curative treatment of COPD exacerbation and to a prognostic and / or diagnostic test for use in the detection of one or more indicator(s) to the probable onset of a COPD exacerbation.
Owner:BLAIR EDWARD DUNCAN +2
System and method for monitoring cardiopulmonary fluid transfer rates using an implantable medical device
Techniques are provided for use by a pacemaker or other implantable medical device for detecting and tracking trends in cardiopulmonary fluid transfer rates—such as heart-to-lung fluid perfusion rates and lung-to-lymphatic system fluid excretion rates—and for detecting heart failure, dyspnea or other cardiopulmonary conditions. In one example, the device periodically measures transthoracic admittance values. A first exponential time-constant (k1) is determined using curve-fitting from admittance values obtained while the patient is in a sleep posture. Time-constant k1 is representative of the fluid perfusion rate. A second exponential time-constant (k2) is determined based on admittance values obtained while the patient is standing / walking / sitting. The second exponential time-constant (k2) is representative of the fluid excretion rate from the lungs. The device then detects trends, if any, in the time-constants (or in “DC” baseline values) to detect or predict medical conditions such as an imminent heart failure exacerbation.
Owner:PACESETTER INC
Chinese medicinal composition for treating cholecystitis diseases and preparation method thereof
InactiveCN101843882AAchieve standardizationAchieve scaleDigestive systemUnknown materialsDiseaseIndian saffron
Owner:TAIYI HEPU BEIJING RES INST OF TCM
Galactoside inhibitor of galectins
Owner:GALECTO BIOTECH
Oral enteric preparation containing Grel drugs and aspirin
The invention relates to a novel oral enteric preparation which is composed of 0.1-1000mg of Grel drugs, or medically acceptable salts, ester or derivatives, 37.5-325mg of aspirin and at least one medically acceptable load, wherein the Grel drugs, or medically acceptable salts, esters or derivatives are clopidogrel, prasugrel, brilinta, sarpogrelate, ozagrel, anagrelide, pamicogrel, or medically acceptable salts, ester or derivatives, preferably, clopidogrel sulfate. The oral enteric preparation is used for curing acute coronary syndrome (ACS), angor pectoris, stroke, myocardial infarction or cardia cerebrovascular diseases of patients. According to the oral enteric preparation, adverse reactions such as functional gastrointestinal disorders, nausea, vomit, gastritis, concealed hemorrhage, ulcer exacerbation and gastrointestinal bleeding caused by strong stimulus of aspirin to stomach can be avoided.
Owner:王定豪
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com